Eli Lilly's oncology R&D spree continues with $576M deal to buy a startup and reel back Aurora A drug
Eli Lilly’s oncology deal spree is continuing this morning with a $576 million deal to buy out a Montreal-based startup and reel back in an early-stage cancer drug for its pipeline.
Lilly, which has been beefing up its cancer R&D group in anticipation of a burst of new projects in the field, is paying $111 million up front to buy Montreal-based AurKa Pharma with another $465 million in milestones on the table.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.